Tag: Acromegaly

Growth hormone binding protein and acid labile subunit levels in the assessment of acromegaly treatment

Posted on by

Marinella Tzanela, Marieta Christoforaki, Lida Papastathopoulou, Dimitra Vassiliadi, Effie Botoula, Panagiotis Trivizas, Nikos C. Thalassinos

Download PDF

Objective: Post-treatment monitoring of acromegalic patients is a matter of controversy, as discrepancies between GH and IGF-I levels have been reported. The aim of our study was to evaluate the role of acid-labile subunit (ALS), a component of the 150 kD IGF-I/IGFBP-3/ALS complex, and the growth hormone binding protein (GHBP) in the follow-up of patients with acromegaly after therapeutic intervention…

Pegvisomant: a new treatment modality for acromegaly

Posted on by

Niki Karavitaki, John AH Wass

Download PDF

Acromegaly, a multisystemic disease resulting from excessive growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels in adults, is associated with a two-to-threefold increase in mortality. The available treatment options (surgery, radiotherapy and medical treatment with somatostatin analogues or dopamine agonists) fail to achieve the currently accepted goals of therapy in a substantial number of patients …

Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period

Posted on by

Olga Karapanou, Marinella Tzanela, Marietta Christoforaki, Lida Papastathopoulou, Paraskevi Moutsatsou, Efi Botoula, Stylianos Tsagarakis

Download PDF

OBJECTIVE: To evaluate the therapeutic trends and long-term outcome of treatment modalities for acromegaly in our center over a 40-year period. Design: We retrospectively studied 321 acromegalic patients (145 males/176 females) diagnosed and treated from the 1970s until September 2013 …

Disappearance of a GH secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal

Posted on by

Sarantis Livadas, Dimitrios J. Hadjidakis, Maria I. Argyropoulou, Maria Stamatelatou, Dimitrios Kelekis, Sotirios A. Raptis

Download PDF

Acromegaly is caused by excessive growth hormone secretion, usually from a pituitary adenoma. The use of somatostatin analogues as primary or adjunctive therapy has been widely applied in the management of acromegaly. We are aware of only three reported cases of complete shrinkage of a pituitary adenoma after long-term analogue administration…

Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center

Posted on by

Monica Livia Gheorghiu, Simona Găloiu, Mădălina Vintilă, Mariana Purice, Dan Hortopan, Anda Dumitraşcu, Mihail Coculescu, Cătălina Poiană

Download PDF

BACKGROUND: Somatostatin analogs (SSA) are now considered standard therapy for acromegaly, as primary or adjunctive treatment after pituitary surgery. OBJECTIVE: To evaluate the efficacy of SSA and the effect of dose escalation in non-operated patients with acromegaly as compared to patients treated after pituitary surgery in a Romanian tertiary care center …

Diagnostic features and outcome of surgical therapy of acromegalic patients: Experience of the last three decades

Posted on by

Elisa Sala, Emanuele Ferrante, Marco Locatelli, Paolo Rampini, Giovanna Mantovani, Claudia Giavoli, Marcello Filopanti, Elisa Verrua, Elena Malchiodi, Giorgio Carrabba, Maura Arosio, Paolo Beck-Peccoz, Anna Spada, Andrea Gerardo Lania

Download PDF

OBJECTIVE: Transsphenoidal (TNS) surgery remains the primary therapeutic option for GH-secreting pituitary adenomas. The aims of this study were to verify the impact of TNS surgery on treatment of acromegaly before and after identification by a dedicated neurosurgical team and to enumerate diagnostic features …

The depiction of acromegaly in ancient Greek and Hellenistic art

Posted on by

Konstantinos Laios, Maria Zozolou, Konstantinos Markatos, Marianna Karamanou, George Androutsos

Download PDF

In 1886, Pierre Marie (1853-1940) published the first accurate scientific description of acromegaly while also coining the term that we now employ (acromegaly today being used when the disease appears in adulthood, and gigantism when it is seen in childhood) …

Cyclopes and Giants: From Homer’s Odyssey to contemporary genetic diagnosis

Posted on by

Georgios K. Markantes, Anastasia Theodoropoulou, Anastasia K. Armeni, Vasiliki Vasileiou, Constantine A. Stratakis, Neoklis A. Georgopoulos

Download PDF

Giant is a term used to describe a legendary humanlike being of great stature and strength. In Greek mythology, the giants Cyclopes rebelled against the Olympian Gods in a battle that ended in their final defeat, this resulting in Olympian sovereignty on earth …

Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control

Posted on by

Ilan Shimon, Wolfgang Saeger, Luiz Eduardo Wildemberg, Monica R. Gadelha

Download PDF

OBJECTIVE: To present two female patients with acromegaly inadequately controlled with long-acting octreotide who were subsequently treated with the multireceptor-targeted somatostatin analogue pasireotide that over-suppressed IGF-1 levels. METHODS: We report two patients who failed surgery and received long-acting octreotide 20-30 mg/month as part of two double-blind, Phase III clinical trials. After 6-12 months of octreotide treatment, both patients remained inadequately controlled and were switched …